BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that physicians at the CIRSE conference reported microwave ablation treatment has the potential to become a primary first-line treatment option for certain tumors because of its efficacy, safety, ease of use, and low cost. CIRSE (Cardiovascular and Interventional Radiological Society of Europe), which was held in Lisbon, Portugal, September 15-19, 2012, is the world's largest and most prestigious conference in the field of minimally invasive image-guided therapies. Over 6,000 medical professionals from 80 countries attended CIRSE, reflecting the global impact of the rapidly expanding field of interventional radiology. The soft tissue ablation world market potential is estimated to exceed $2.3 billion.
During CIRSE BSD sponsored a series of tumor ablation workshops that provided hands-on demonstrations of the MicroThermX® Microwave Ablation System's (MicroThermX®) advanced technology. The multiple configurations of the MicroThermX® provide physicians the ability to precisely target the ablation zone to the numerous sizes and shapes of diseased tissue, significantly increasing the number of cases that can be treated with microwave ablation. There was standing room only at the Company's workshops, and the significant interest in MicroThermX® was evident by the constant stream of interested clinicians and medical distributors from around the world.
About the MicroThermX® Microwave Ablation System
The MicroThermX® is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX® is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX® utilizes innovative synchronous phased array technology developed and patented by BSD to provide larger, more uniform zones of ablation during a single procedure. The MicroThermX® introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX® for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX®, which allows BSD to market the MicroThermX®in Europe. CE marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX®to a number of international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.